DekaBank Deutsche Girozentrale Has $1.55 Million Stock Holdings in Merus (NASDAQ:MRUS)

DekaBank Deutsche Girozentrale increased its stake in shares of Merus (NASDAQ:MRUS - Free Report) by 124.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 56,000 shares of the biotechnology company's stock after purchasing an additional 31,000 shares during the quarter. DekaBank Deutsche Girozentrale owned 0.10% of Merus worth $1,547,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. BluePath Capital Management LLC acquired a new stake in Merus in the third quarter valued at $33,000. China Universal Asset Management Co. Ltd. increased its position in Merus by 142.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,477 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 867 shares in the last quarter. JPMorgan Chase & Co. increased its position in Merus by 871.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,564 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 1,403 shares in the last quarter. Coppell Advisory Solutions LLC purchased a new stake in Merus during the 2nd quarter worth about $47,000. Finally, BNP Paribas Arbitrage SA boosted its stake in Merus by 107.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 1,811 shares of the biotechnology company's stock worth $41,000 after buying an additional 938 shares during the last quarter. 96.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

MRUS has been the topic of a number of research analyst reports. Stifel Nicolaus raised their price target on Merus from $40.00 to $65.00 and gave the stock a "buy" rating in a research note on Thursday, February 29th. StockNews.com lowered Merus from a "hold" rating to a "sell" rating in a research note on Monday, March 4th. HC Wainwright lifted their price objective on Merus from $48.00 to $65.00 and gave the company a "buy" rating in a research note on Thursday, February 29th. Truist Financial assumed coverage on Merus in a research note on Thursday, March 28th. They issued a "buy" rating and a $69.00 price objective on the stock. Finally, BMO Capital Markets lifted their price objective on Merus from $49.00 to $58.00 and gave the company an "outperform" rating in a research note on Thursday, February 29th. One equities research analyst has rated the stock with a sell rating and eleven have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $55.50.

Merus Stock Performance

Merus stock traded down $0.58 during midday trading on Monday, hitting $41.27. 270,965 shares of the company were exchanged, compared to its average volume of 571,894. The company's fifty day moving average price is $44.85 and its 200-day moving average price is $32.62. Merus has a fifty-two week low of $18.21 and a fifty-two week high of $52.03.

Merus (NASDAQ:MRUS - Get Free Report) last released its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.38). The company had revenue of $8.94 million for the quarter, compared to analyst estimates of $10.43 million. Merus had a negative return on equity of 50.61% and a negative net margin of 352.56%. As a group, sell-side analysts expect that Merus will post -3.29 EPS for the current fiscal year.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.